Evogene Ltd (NYSE:EVGN) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Evogene Ltd (NYSE:EVGN) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.05, Morningstar.com reports. Evogene had a negative return on equity of 18.60% and a negative net margin of 235.47%. The company had revenue of $1.18 million for the quarter.

Evogene (NYSE EVGN) opened at 4.75 on Friday. The company’s market capitalization is $121.72 million. Evogene has a 12-month low of $4.57 and a 12-month high of $7.09. The company has a 50-day moving average of $5.04 and a 200 day moving average of $5.15.

WARNING: This piece of content was reported by [[site]] and is owned by of [[site]]. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at [[permalink]].

A number of hedge funds have recently made changes to their positions in EVGN. Canada Pension Plan Investment Board boosted its stake in shares of Evogene by 142.9% in the second quarter. Canada Pension Plan Investment Board now owns 680,000 shares of the biotechnology company’s stock worth $3,414,000 after buying an additional 400,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Evogene by 59.6% in the first quarter. Goldman Sachs Group Inc. now owns 606,962 shares of the biotechnology company’s stock worth $3,246,000 after buying an additional 226,778 shares in the last quarter. UBS Group AG boosted its stake in shares of Evogene by 10.1% in the first quarter. UBS Group AG now owns 1,052,537 shares of the biotechnology company’s stock worth $5,628,000 after buying an additional 96,527 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Evogene by 53.4% in the first quarter. JPMorgan Chase & Co. now owns 245,425 shares of the biotechnology company’s stock worth $4,079,000 after buying an additional 85,425 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Evogene by 5.3% in the first quarter. Bank of America Corp DE now owns 841,552 shares of the biotechnology company’s stock worth $4,500,000 after buying an additional 42,532 shares in the last quarter. 29.88% of the stock is owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.